For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...

Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...

Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...